Dolat Capital: Vinati Organics’ Q1 Earnings Shows Disappointment On All Fronts
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Vinati Organics Ltd.’s Q1 FY21 earnings print showed a disappointment on all fronts. Sales de-grew by 20.4% YoY to Rs 2.31billion (our estimat Rs 2.46 billion).
Ebitda de-growth came in at 19.1% to Rs 972 million (our estimate Rs 903 million). Profit after tax de-growth was cushioned by a lower tax rate of 24% in Q1 FY21 against 34% in Q1 F20, Profit after tax de-growth was at 12.2% YoY to Rs 723 million.
Gross margins and Ebitda margins were at a record high level of 63.4% and 42.0% up by 628 basis points and 70 basis points YoY.
Ebitda margins improved on three accounts,
a) Low cost inventory of Methyl Tertiary Butyl Ether for March 2020, which led to margin expansion in Acrylamide tertiary-butyl sulfonic acid (ATBS),
b) Operating leverage in Isobutyl Benzene (IBB), which was absent in FY20,
c) Incremental sales coming from customized products (high margin products), which were absent in FY20.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.